GENB Insider Trading Activity and SEC Form 4 Filings
GENB insider trading summary
Over the past 12 months, insiders at Generate Biomedicines, Inc. (GENB) reported 50 open-market purchases worth $1.13B by 18 insiders and 2 sales worth $201K by 1 insider on SEC Form 4. Net insider buying was $1.13B.
Latest GENB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 29, 2026 | Frances Arnold | Insider | Sell | $185K (11,409 @ $16.19) |
| Sep 1, 2026 | Frances Arnold | Insider | Sell | $16K (1,000 @ $16.00) |
| Mar 4, 2026 | Michael Nally | Chief Executive Officer | Buy | $240K (20,000 @ $12.00) |
| Mar 2, 2026 | Flagship Pioneering, LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | Nutritional Health LTP Fund General Partner LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | Flagship Pioneering Special Opportunities Fund II General Partner LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | Flagship Pioneering Fund VII General Partner LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | Noubar Afeyan | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | Flagship Pioneering, LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
| Mar 2, 2026 | FPN General Partner LLC | Insider | Buy | $25.0M (1,562,500 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.